Maravai LifeSciences Raises 2026 Guidance as Q1 Revenue Jumps 41%, EBITDA Hits $20.3M
summarizeSummary
Maravai LifeSciences reported strong first-quarter 2026 results, with revenue increasing 40.5% year-over-year to $65.8 million and Adjusted EBITDA reaching $20.3 million. Crucially, the company returned to positive free cash flow of $4.2 million and raised its full-year 2026 guidance for both revenue and Adjusted EBITDA. This performance marks a significant positive shift from the substantial declines in revenue and negative Adjusted EBITDA reported in the prior year's 10-K, indicating a strong operational turnaround. The robust growth, particularly in the TriLink segment driven by CleanCap orders for COVID-19 vaccines, and improved profitability metrics are highly material and likely to drive positive investor sentiment and stock price appreciation. Traders will be watching for sustained growth in the TriLink segment and continued operational efficiency in subsequent quarters.
At the time of this announcement, MRVI was trading at $4.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.95 to $4.11. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.